Panduan definitif tentang penyuntingan gen.
Menu
Beranda Pelajari Berita Tanya Atlas
Jelajahi Teknologi Penyakit Perawatan Uji Klinis Perusahaan Ilmuwan Gen-gen Penelitian Institusi
Di luar dunia medis Pertanian Etika Investasi Peta dunia
Pelajari & Alat Mulai di sini Glosarium A–Z Bandingkan teknologi Linimasa Daftar & Peringkat Agen AI ★ Tersimpan API
Tentang Tentang kami Metodologi Sumber Data Kebijakan Editorial Kontak Penafian

🧭 Tampilan Terpandu
Baru mengenal genetika? Kami menjelaskan setiap istilah saat kamu menjelajah, dalam bahasa yang mudah dipahami. Halaman yang sama, dengan bantuan yang sudah tersedia.

⚡ Pandangan Ahli
Kamu sudah mengenal biologinya. Cukup kontennya — ringkas dan padat, tanpa penjelasan tambahan. Ini adalah tampilan default.

Bahasa antarmuka
Mode terang

Perbandingan

CRISPR vs RNA Interference

A permanent change to the instructions, against a temporary attack on the copies.

Perbedaannya dalam satu kalimat

Both can reduce how much of a protein your body makes. CRISPR does it by changing the gene — once, permanently. RNA interference does it by destroying the working copies as they are made, which means repeating the treatment indefinitely but also being able to stop. For ATTR amyloidosis both approaches target the same gene, which makes the comparison unusually concrete.

AspekCRISPR gene editingRNA interference
What it changes The gene itself The messages made from the gene
Permanence Permanent Temporary — repeat dosing required
Can it be stopped? No Yes — stop dosing and it wears off
Dosing Once Regularly, indefinitely
Safety data available A few years Years, from approved medicines in routine use
Clinical status One approved medicine Multiple approved medicines
Same-target example Nexiguran ziclumeran for ATTR Patisiran and vutrisiran for ATTR

Which is better?

Neither, in general. The editing approach offers one treatment instead of a lifetime of them. The RNAi approach offers years of accumulated safety data and the ability to stop if something goes wrong. For a young patient facing decades of injections, permanence looks attractive; for an older patient with other conditions, reversibility may matter more. It is the clearest illustration on this site that newer does not settle a clinical question.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

RNA Interference

Diseases

ATTR Amyloidosis